top signin

Pin It
interior-banner-mask

 

.

Press Releases

Oct 25, 2022

Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ R...

Extends core IP from tubes to patches and from regenerating the esophagus after esophagectomy to treating fistulas and strictures anywhere in the GI tract including the esophagus, stomach and...


Aug 08, 2022

Biostage Announces Appointment of New Chief Financial Officer...

HOLLISTON, Mass., Aug. 8, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating...


Aug 04, 2022

Biostage Reports Corporate Highlights and Second Quarter Financial Results...

HOLLISTON, Mass., Aug. 4, 2022 /PRNewswire/ --Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal...


Aug 04, 2022

Biostage Schedules Conference Call and Webcast for Q2 2022 Results...

HOLLISTON, Mass., Aug. 4, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...


Jun 15, 2022

Biostage Announces Publication of Mechanical Strength Data for Regenerated Esoph...

The current study tested the biomechanical strength of the newly regenerated esophageal tissue and demonstrated that the strength of the tissue was comparable to adjacent native tissue.   HOLLISTON,...


May 16, 2022

Biostage Reports Q1 2022 Financial Results and Corporate Highlights...

HOLLISTON, Mass., May 16, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...


May 13, 2022

Biostage Announces $5.1 Million Financing to Advance Clinical Trial...

HOLLISTON, Mass. , May 13, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...


May 10, 2022

Biostage Schedules Conference Call and Webcast for Q1 2022 Results...

HOLLISTON, Mass., May 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...


Apr 11, 2022

Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneratio...

Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer.   HOLLISTON, Mass., April 11, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...


Apr 01, 2022

Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results...

HOLLISTON, Mass., April 1, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...